利拉鲁肽调节2型糖尿病的代谢紊乱  

Liraglutide regulates the metabolic disorders of the patients with type 2 diabetes mellitus

作　　者：李洋[1] 张建中[1] 赵文成[1] 门岚[1] 马媛[1] 张颖[1] 王丽芬[1] 

机构地区：[1]吉林大学中日联谊医院新民院区内分泌科,吉林长春130021

出　　处：《吉林医学》2014年第4期715-717,共3页Jilin Medical Journal

摘　　要：目的:研究利拉鲁肽(胰高血糖素样肽-1类似物)调节2型糖尿病的代谢紊乱。方法:采用随机、开放、对照的原则对均采用生活方式干预加胰岛素联合治疗血糖控制不达标的2型糖尿病患者进行分组,住院后联合应用利拉鲁肽的2型糖尿病患者30例作为治疗组,同期住院未联合应用利拉鲁肽的2型糖尿病患者30例作为对照组,治疗3个月后并对两组患者治疗前后组内及组间空腹血糖、餐后2 h血糖、糖化血红蛋白、体重指数、血压、血脂、胰岛素用量、不良反应等指标进行分析。结果:两组内比较治疗组与对照组的治疗后空腹血糖、餐后2 h血糖、糖化血红蛋白、收缩压、舒张压均较治疗前下降,差异有统计学意义(P<0.05);两组间比较治疗后餐后2 h血糖、糖化血红蛋白、体重指数、胰岛素总量治疗组较对照组下降,高密度脂蛋白治疗组较对照组升高,差异有统计学意义(P<0.05);治疗组中3例患者在治疗早期有恶心、腹泻等胃肠道不良反应,可耐受,低血糖发生率较对照组降低。结论:利拉鲁肽能够良好调节2型糖尿病患者的代谢紊乱,尤其以餐后血糖作用为主,体重下降明显,有效减少胰岛素总量,消化道不良反应轻,低血糖发生率低。Objective To study the metabolic disorders of the patients with type 2 diabetes mellitus （T2DM） regulated by Liraglutide （ Glucagon - like Peptide - 1 recePtor agonists）. Method A randomized, open, parallel controlled trial was conducted in the group of the non - satisfactory controlling of blood glucose patients with T2DM, who had been treated with life behavior intervention and insulin injec- tion, which were divided into two groups, the treatment group with Liraglutide （30 cases） and control group without Liraglutide （30 cases）, during the same period. After 3 months treatment fasting blood glucose （FBG） ,2 -hour postprandial blood glucose （2hPBG）, glycosylated hemoglobin A1 c （HbA1 c）, body mass index （BMI）, blood press,.~e, serum lipid,the dosage of insulin and the adverse reactions were as- sessed prior and post treatment between intra -group and inter- group. Results FBG,2hPBG, HbAlc,systolic blood pressure （SBP） ,dias- tolic blood pressure （DBP） were decreased prior and post treatment in the intra - group comparison respectively （ P 〈 0. 05）. In the inter - group comparison pest treatment ,2hPBG, HbA1 c, BMI, the dosage of insulin in the treatment group were significantly lower than those in the control group,while high- density lipeprotein （HDL） was higher （P 〈 0. 05）. In the treatment group,three patients suffered from nausea and diarrhea, but the incidence of hypoglycemia was obviously lower than control group. Conclusion Liraglutide can well regulate the meta- bolic disorders of the patients with T2DM. especially in the control of 2hPBG, and weight and the dosage of insulin are significantly de- creased. The adverse reactions are slight and hypoglycemia incidence is low.

关 键 词：利拉鲁肽 胰高血糖素样肽-1类似物 2型糖尿病 代谢紊乱 胰岛素 

分 类 号：R587.1[医药卫生—内分泌]